- Home
- EQBK vs ABVX Comparison
EQBK vs ABVX Comparison
Compare EQBK & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQBK
- ABVX
- Stock Information
- Founded
- EQBK 2002
- ABVX 2013
- Country
- EQBK United States
- ABVX France
- Employees
- EQBK N/A
- ABVX N/A
- Industry
- EQBK Major Banks
- ABVX
- Sector
- EQBK Finance
- ABVX
- Exchange
- EQBK Nasdaq
- ABVX Nasdaq
- Market Cap
- EQBK 750.4M
- ABVX 722.3M
- IPO Year
- EQBK 2015
- ABVX N/A
- Fundamental
- Price
- EQBK $43.12
- ABVX $6.16
- Analyst Decision
- EQBK Hold
- ABVX Strong Buy
- Analyst Count
- EQBK 4
- ABVX 7
- Target Price
- EQBK $44.50
- ABVX $37.86
- AVG Volume (30 Days)
- EQBK 84.6K
- ABVX 216.6K
- Earning Date
- EQBK 01-22-2025
- ABVX 09-09-2024
- Dividend Yield
- EQBK 1.25%
- ABVX N/A
- EPS Growth
- EQBK N/A
- ABVX N/A
- EPS
- EQBK 1.12
- ABVX N/A
- Revenue
- EQBK $157,755,000.00
- ABVX $9,676,417.00
- Revenue This Year
- EQBK N/A
- ABVX $31.67
- Revenue Next Year
- EQBK $6.05
- ABVX $759.77
- P/E Ratio
- EQBK $38.46
- ABVX N/A
- Revenue Growth
- EQBK N/A
- ABVX 100.87
- 52 Week Low
- EQBK $30.44
- ABVX $5.54
- 52 Week High
- EQBK $50.85
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- EQBK 50.11
- ABVX 30.30
- Support Level
- EQBK $39.26
- ABVX $5.54
- Resistance Level
- EQBK $43.27
- ABVX $6.46
- Average True Range (ATR)
- EQBK 1.07
- ABVX 0.51
- MACD
- EQBK 0.28
- ABVX -0.04
- Stochastic Oscillator
- EQBK 85.02
- ABVX 30.10
About EQBK Equity Bancshares Inc.
Equity Bancshares Inc is a bank holding company. The company's operation involves the delivery of loan and deposit products to customers. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.